Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03334422
Registration number
NCT03334422
Ethics application status
Date submitted
3/11/2017
Date registered
7/11/2017
Titles & IDs
Public title
Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Query!
Secondary ID [1]
0
0
I4V-MC-JAHM
Query!
Secondary ID [2]
0
0
16581
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BREEZE-AD2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Baricitinib
Treatment: Drugs - Placebo
Experimental: 4 Milligram (mg) Baricitinib - 4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
Experimental: 2mg Baricitinib - 2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
Experimental: 1mg Baricitinib - 1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
Placebo comparator: Placebo - Placebo administered orally once daily.
Treatment: Drugs: Baricitinib
Administered orally
Treatment: Drugs: Placebo
Administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a = 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib)
Query!
Assessment method [1]
0
0
The IGA measures the investigator's global assessment of the participants overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [1]
0
0
16 Weeks
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving IGA of 0 or 1 With a = 2 Point Improvement (Placebo, 1mg Baricitinib)
Query!
Assessment method [1]
0
0
The IGA measures the investigator's global assessment of the participants overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [1]
0
0
16 Weeks
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)
Query!
Assessment method [2]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score is obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a = 75% improvement from baseline in the EASI score.
Query!
Timepoint [2]
0
0
16 Weeks
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving EASI90
Query!
Assessment method [3]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (1) erythema, (2)edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score is obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a = 90% improvement from baseline in the EASI score.
Query!
Timepoint [3]
0
0
16 Weeks
Query!
Secondary outcome [4]
0
0
Percent Change From Baseline on EASI Score
Query!
Assessment method [4]
0
0
The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs (1) erythema (2)edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score is obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).
Least Square (LS) Means were calculated using a mixed model repeated measures (MMRM) model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [4]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)
Query!
Assessment method [5]
0
0
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable Itching or lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a = 75% improvement from baseline in the SCORAD score.
Query!
Timepoint [5]
0
0
16 Weeks
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)
Query!
Assessment method [6]
0
0
The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
Query!
Timepoint [6]
0
0
16 Weeks
Query!
Secondary outcome [7]
0
0
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)
Query!
Assessment method [7]
0
0
Atopic Dermatitis Sleep Scale (ADSS) is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep, frequency of waking, and difficulty getting back to sleep last night. Item 2, frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually.
LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.
Query!
Timepoint [7]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [8]
0
0
Change From Baseline in Skin Pain NRS
Query!
Assessment method [8]
0
0
Skin Pain NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours.
LSMean was calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [8]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving EASI50
Query!
Assessment method [9]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs (1) erythema, (2)edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI 50 is defined as =50% improvement from baseline in EASI score.
Query!
Timepoint [9]
0
0
16 Weeks
Query!
Secondary outcome [10]
0
0
Percentage of Participants Achieving IGA of 0
Query!
Assessment method [10]
0
0
The IGA measures the investigator's global assessment of the participants overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [10]
0
0
16 Weeks
Query!
Secondary outcome [11]
0
0
Change From Baseline in SCORAD
Query!
Assessment method [11]
0
0
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LSMeans was calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [11]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [12]
0
0
Percentage of Participants Achieving SCORAD90
Query!
Assessment method [12]
0
0
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.
SCORAD90 defined as a = 90% improvement from baseline in the SCORAD score.
Query!
Timepoint [12]
0
0
16 Weeks
Query!
Secondary outcome [13]
0
0
Change From Baseline in Body Surface Area (BSA) Affected
Query!
Assessment method [13]
0
0
Body surface area affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions.
Use the percentage of skin affected for each region (0 to 100%) in EASI as follows:
BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [13]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [14]
0
0
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment
Query!
Assessment method [14]
0
0
Percentage of participants developing skin infections requiring antibiotic treatment.
Query!
Timepoint [14]
0
0
16 Weeks
Query!
Secondary outcome [15]
0
0
Percent Change From Baseline in Itch NRS
Query!
Assessment method [15]
0
0
The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [15]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [16]
0
0
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)
Query!
Assessment method [16]
0
0
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [16]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [17]
0
0
Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score
Query!
Assessment method [17]
0
0
The PGI-S-AD asked the participant to evaluate the severity of the disease at that point in time on a single-item, 5-point scale, using a daily diary. The same category labels used in the Physician's Global Assessment were used for the PGI-S-AD, ie, "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [17]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [18]
0
0
Change From Baseline on the Hospital Anxiety and Depression Scale (HADS)
Query!
Assessment method [18]
0
0
The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 items questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [18]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [19]
0
0
Change From Baseline on the Dermatology Life Quality Index (DLQI)
Query!
Assessment method [19]
0
0
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Scores range from 0 to 30 (less to more impairment), and a 4-point change from baseline is considered as the minimal clinically important difference threshold.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [19]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [20]
0
0
Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire
Query!
Assessment method [20]
0
0
The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [20]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [21]
0
0
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
Query!
Assessment method [21]
0
0
EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [21]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [22]
0
0
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)
Query!
Assessment method [22]
0
0
EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
LSMean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, \& treatment-by-visit-interaction as fixed categorical effects. Baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [22]
0
0
Baseline, 16 Weeks
Query!
Secondary outcome [23]
0
0
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a = 2 Point Improvement
Query!
Assessment method [23]
0
0
The IGA measures the investigator's global assessment of the participants overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [23]
0
0
4 Weeks
Query!
Eligibility
Key inclusion criteria
* Have been diagnosed with moderate to severe Atopic Dermatitis for at least 12 months.
* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
* Agree to use emollients daily.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.
* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
* Have been treated with the following therapies:
* Monoclonal antibody for less than 5 half-lives prior to randomization.
* Received prior treatment with any oral Janus kinase (JAK) inhibitor.
* Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
* Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.
* Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
* Have had major surgery within the past eight weeks or are planning major surgery during the study.
* Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
* Have a history of recurrent (= 2) VTE or are considered at high risk of VTE as deemed by the investigator.
* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
* Have specific laboratory abnormalities.
* Have received certain treatments that are contraindicated.
* Pregnant or breastfeeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/11/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/12/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
615
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Woden Dermatology - Phillip
Query!
Recruitment hospital [2]
0
0
Skin & Cancer Foundation Australia - Westmead
Query!
Recruitment hospital [3]
0
0
Veracity Clinical Research Pty Ltd - Woolloongabba
Query!
Recruitment hospital [4]
0
0
Clinical Trials SA Pty Ltd - Adelaide
Query!
Recruitment hospital [5]
0
0
Skin and Cancer Foundation Inc. - Carlton
Query!
Recruitment hospital [6]
0
0
Fremantle Dermatology - Perth
Query!
Recruitment postcode(s) [1]
0
0
2606 - Phillip
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
5073 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [6]
0
0
6160 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Buenos Aires
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
Mendoza
Query!
Country [4]
0
0
Austria
Query!
State/province [4]
0
0
Oberösterreich
Query!
Country [5]
0
0
Austria
Query!
State/province [5]
0
0
Wien
Query!
Country [6]
0
0
Hungary
Query!
State/province [6]
0
0
Csongrad
Query!
Country [7]
0
0
Hungary
Query!
State/province [7]
0
0
Hajdu-Bihar
Query!
Country [8]
0
0
Hungary
Query!
State/province [8]
0
0
Jasz-Nagykun-Szolnok
Query!
Country [9]
0
0
Hungary
Query!
State/province [9]
0
0
Budapest
Query!
Country [10]
0
0
Hungary
Query!
State/province [10]
0
0
Kaposvar
Query!
Country [11]
0
0
Hungary
Query!
State/province [11]
0
0
Oroshaza
Query!
Country [12]
0
0
Hungary
Query!
State/province [12]
0
0
Szombathely
Query!
Country [13]
0
0
Hungary
Query!
State/province [13]
0
0
Veszprem
Query!
Country [14]
0
0
Israel
Query!
State/province [14]
0
0
Afula
Query!
Country [15]
0
0
Israel
Query!
State/province [15]
0
0
Haifa
Query!
Country [16]
0
0
Israel
Query!
State/province [16]
0
0
Jerusalem
Query!
Country [17]
0
0
Israel
Query!
State/province [17]
0
0
Petach Tikva
Query!
Country [18]
0
0
Israel
Query!
State/province [18]
0
0
Ramat Gan
Query!
Country [19]
0
0
Israel
Query!
State/province [19]
0
0
Tel Aviv
Query!
Country [20]
0
0
Japan
Query!
State/province [20]
0
0
Chiba
Query!
Country [21]
0
0
Japan
Query!
State/province [21]
0
0
Fukuoka
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Hokkaido
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Ibaraki
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Kanagawa
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Kumamoto
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Osaka
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Saitama
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Tochigi
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Tokyo
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Gifu
Query!
Country [31]
0
0
Korea, Republic of
Query!
State/province [31]
0
0
Gyeonggi Do
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Korea
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Seoul
Query!
Country [34]
0
0
Poland
Query!
State/province [34]
0
0
Bialystok
Query!
Country [35]
0
0
Poland
Query!
State/province [35]
0
0
Gdansk
Query!
Country [36]
0
0
Poland
Query!
State/province [36]
0
0
Katowice
Query!
Country [37]
0
0
Poland
Query!
State/province [37]
0
0
Krakow
Query!
Country [38]
0
0
Poland
Query!
State/province [38]
0
0
Lodz
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Olsztyn
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Osielsko
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Szczecin
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Warsaw
Query!
Country [43]
0
0
Poland
Query!
State/province [43]
0
0
Warszawa
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Badalona
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Madrid
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Navarra
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Alicante
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Pontevedra
Query!
Country [49]
0
0
Switzerland
Query!
State/province [49]
0
0
Vaud
Query!
Country [50]
0
0
Switzerland
Query!
State/province [50]
0
0
Bern
Query!
Country [51]
0
0
Switzerland
Query!
State/province [51]
0
0
Genève
Query!
Country [52]
0
0
Switzerland
Query!
State/province [52]
0
0
Zürich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Incyte Corporation
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03334422
Query!
Trial related presentations / publications
Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18. Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021 Oct 23;19(1):247. doi: 10.1186/s12955-021-01877-8. Thyssen JP, Buhl T, Fernandez-Penas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Stander S. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577-x. Epub 2021 Jul 18. Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Penas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatol Ther (Heidelb). 2021 Jun;11(3):971-982. doi: 10.1007/s13555-021-00534-8. Epub 2021 Apr 25. King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, Watts SD, Chen YF, Simpson EL, Silverberg JI. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2022 May;33(3):1521-1530. doi: 10.1080/09546634.2020.1839008. Epub 2020 Nov 22.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Query!
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/22/NCT03334422/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/22/NCT03334422/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03334422